Key Highlights

  • The NEUTRALIZE-AKI pivotal trial has enrolled nearly 75% of its intended 339 patients.
  • A first module of the premarket approval application has been submitted to the FDA.
  • The company holds Breakthrough Device Designation, which could allow priority review.
  • QUELIMMUNE is being used for sepsis-associated acute kidney injury in pediatric patients.

SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on treatments for critically ill patients with organ failure, reported financial results for the three months ended September 30, 2026. The update highlighted growing use of its QUELIMMUNE therapy in pediatric acute kidney injury and progress toward a pivotal trial and a premarket approval application. It was dated November 11, 2026. Pediatric acute kidney injury is a condition with few treatment options, and therapies in that area are developed under regulatory pathways designed for small populations.

QUELIMMUNE Adoption

The company said QUELIMMUNE, also referred to as SCD-PED, is being used to treat sepsis-associated acute kidney injury in pediatric patients, an ultra-rare market. Its critical care team has been presenting at medical meetings to educate clinicians on the therapy.

The company also shared data from a late-breaking presentation at ASN Kidney Week 2026, which it said showed statistically significant higher survival in QUELIMMUNE-treated patients. Those are the company's own presentations of trial results and should be read in that context.

Ultra-rare indications typically have small patient numbers, which can make trials slow to enroll and results harder to generalize. The company's emphasis on enrollment progress reflects that practical constraint.

The NEUTRALIZE-AKI Pivotal Trial

The NEUTRALIZE-AKI pivotal trial has enrolled nearly 75% of its intended 339 patients, according to the update. Enrollment is a central milestone because the full dataset is needed to support the approval decision.

The company has submitted the first module of its premarket approval application to the FDA. It said the modular approach should speed review, since the final module with pivotal results is the piece that completes the submission.

A modular premarket approval submission allows parts of an application to be filed as they are completed, which can shorten the final review. The company's first module is now with the FDA, though the agency's review timetable is not stated.

Breakthrough Designation and Review Timing

SeaStar holds Breakthrough Device Designation for this indication, which it says would allow priority review once the final module is submitted with pivotal results, provided the trial outcome is positive. Priority review is not guaranteed and depends on the results.

The timing of the final submission depends on completing enrollment and analyzing the data. Neither milestone has a date in the update, so the approval timeline cannot be fixed from the material reviewed.

Breakthrough designation can speed interactions with the FDA, but it does not guarantee approval. The trial results will determine whether the designation translates into a faster review.

Financial Position and Open Questions

The sections of the update reviewed do not state SeaStar's cash position or quarterly loss, so funding needs cannot be assessed from them. Pediatric indications with small patient populations often depend on regulatory timing and reimbursement, and the update does not address either topic in detail.

The next updates should show enrollment completion, the remaining application modules and any financing activity that supports the trial through its final readout.

Commercial use of QUELIMMUNE in a small market means Revenue will depend on the number of treating centers and patients. The update does not provide patient counts or sales figures.

Final Word

SeaStar Medical's third-quarter update points to a therapy in use within a narrow pediatric market and a pivotal trial that is most of the way to full enrollment. Approval timing depends on completing the trial, submitting the final application module and the trial outcome itself. Investors and clinicians will look for enrollment completion and the final dataset. Enrollment completion and the final submission will be the next checkpoints for the program.